Gilead will integrate Interius, the first biotech to push an in vivo CAR-T therapy into the clinic, into its cell therapy ...

Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...

Gilead has become the latest pharma to strengthen its in-vivo cell therapy credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics. | Gilead has become the latest ...

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could ...

Gilead Sciences agreed to buy Interius BioTherapeutics, a privately held biotechnology company developing in-vivo CAR therapeutics, for $350 million. Gilead on Thursday said the deal complements the ...

A University of Pennsylvania spinout that is developing a faster and cheaper way to modify immune cells to fight cancer will be sold to a unit of Gilead Sciences Inc. for $350 million under an ...

Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access.

The Gilead subsidiary company Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately-held biotechnology company developing in vivo CAR therapeutics, for $350 ...

Kite, a Gilead Company, has agreed to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics.

"We are, of course, disappointed by the FDA's decision to not approve vatiquinone," said Matthew Klein, PTC's chief executive, who noted that the FDA is seeking another 'adequate and well-controlled' ...